Castle Biosciences Inc
$ 25.05
2.00%
17 Apr - close price
- Market Cap 744,069,000 USD
- Current Price $ 25.05
- High / Low $ 25.36 / 24.84
- Stock P/E N/A
- Book Value 15.86
- EPS -0.83
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.05 %
- 52 Week High 44.28
- 52 Week Low 14.59
About
Castle Biosciences Inc. is a cutting-edge diagnostics company dedicated to transforming patient care through its innovative gene-expression profiling tests, particularly in the realm of skin cancer. Its flagship product, DecisionDx®-Melanoma, is instrumental in the management of melanoma, providing critical insights into patient risk stratification and treatment decision-making. With a robust commitment to precision medicine, Castle is actively expanding its portfolio of assays to address unmet clinical needs. Bolstered by a strong research and development focus and an ambitious pipeline, the company is strategically positioned for sustainable growth while enhancing clinical outcomes and delivering significant value to its shareholders in the evolving oncology marketplace.
Analyst Target Price
$48.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-03 | 2025-08-04 | 2025-04-30 | 2025-02-26 | 2024-11-04 | 2024-08-05 | 2024-05-02 | 2024-02-28 | 2023-11-02 | 2023-08-02 | 2023-05-03 |
| Reported EPS | -0.08 | -0.02 | 0.15 | -0.9035 | 0.32 | 0.08 | 0.31 | -0.09 | -0.1 | -0.26 | -0.7 | -1.1 |
| Estimated EPS | -0.32 | -0.52 | -0.51 | -0.0657 | 0.04 | -0.06 | -0.27 | -0.33 | -0.54 | -0.76 | -0.91 | -0.89 |
| Surprise | 0.24 | 0.5 | 0.66 | -0.8378 | 0.28 | 0.14 | 0.58 | 0.24 | 0.44 | 0.5 | 0.21 | -0.21 |
| Surprise Percentage | 75% | 96.1538% | 129.4118% | -1275.1903% | 700% | 233.3333% | 214.8148% | 72.7273% | 81.4815% | 65.7895% | 23.0769% | -23.5955% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.56 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CSTL
2026-04-17 06:09:04
Castle Biosciences, Inc. (NASDAQ:CSTL) has received a "Moderate Buy" consensus rating from ten research firms, with an average one-year price target of $47.57. Recent analyst upgrades and raised price targets include actions from Morgan Stanley, Lake Street, Canaccord, and Guggenheim. The company recently beat quarterly earnings and revenue estimates, though insiders have sold a significant number of shares totaling approximately $2.16 million in the last 90 days.
2026-04-16 08:39:14
Castle Biosciences, Inc. (Nasdaq: CSTL) announced it will release its first quarter 2026 financial results after market close on Wednesday, May 6, 2026. Company management will host a webcast at 4:30 p.m. Eastern time on the same day to discuss the results. The live webcast details are provided, along with information about Castle Biosciences, a diagnostics company focused on dermatologic and gastroenterological diseases.
2026-04-16 02:39:56
Castle Biosciences, Inc. (Nasdaq: CSTL) announced it will release its first quarter 2026 financial results after market close on Wednesday, May 6, 2026. The company will also host a webcast at 4:30 p.m. Eastern time on the same day to discuss these results. Castle Biosciences focuses on innovative tests to guide patient care in dermatologic and gastroenterological diseases.
2026-04-15 11:09:44
Castle Biosciences (Nasdaq: CSTL) announced it will release its first quarter 2026 financial results after market close on Wednesday, May 6, 2026. The company will also host a live webcast at 4:30 p.m. ET on the same day, which will include a brief Q&A session. Investors can access the webcast via the provided link or the company's Investor Relations page.
2026-04-10 20:10:14
Castle Biosciences (NASDAQ:CSTL) saw its share price drop by 7% on Friday, trading at $21.79 on significantly lower than average volume. Despite this decline, Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $47.57, driven by recent upgrades. The company's fundamentals show mixed signals, with beats on quarterly EPS and revenue estimates but negative net margin and P/E, alongside significant insider selling over the past 90 days.
2026-04-10 14:38:55
Castle Biosciences, Inc. (Nasdaq: CSTL) has been awarded the 2026 USA TODAY Top Workplaces USA Award for the fifth consecutive year. This recognition is based on confidential employee feedback and highlights the company's commitment to building a people-first workplace culture. CEO Derek Maetzold emphasized that valuing, supporting, and empowering team members is a continuous investment for the company.
